Compass Therapeutics, Inc. — Director's Dealing 2025

May 27, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Compass Therapeutics, Inc. (CMPX)
CIK: 0001738021
Period of Report: 2025-05-27

Reporting Person: Schuetz Thomas J. (Director, CHIEF EXECUTIVE OFFICER)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-05-27	Common Stock	P	10000	$2.11	Acquired	6480825	Direct

Footnotes

F1: The price reported in Column 4 is the weighted average purchase price. These shares were purchased in two transactions at prices of $2.105 and $2.115 per share. The reporting person hereby undertakes to provide, upon request, to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, full information regarding the number of shares purchased and prices within the range set forth above.

F2: 150,000 of the shares represent unvested RSUs granted on November 16, 2021. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on November 15, 2022. 250,000 of the shares represent unvested RSUs granted on February 8, 2023. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on February 8, 2024. 478,125 of the shares represent unvested RSUs granted on January 9, 2024. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 9, 2025.